XML 57 R48.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value of Financial Instruments - Narrative (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Feb. 20, 2020
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Fair Value, Option, Quantitative Disclosures [Line Items]            
Company acquired right to receive certain future milestone   $ 223,723 $ 101,064 $ 432,603 $ 193,573  
Contingent consideration liabilities   111,500   $ 111,500   $ 86,200
Progenics            
Fair Value, Option, Quantitative Disclosures [Line Items]            
Royalty percentage       0.05    
Aggregate cash payments percentage 40.00%          
Potential payments, high   85,000   $ 85,000    
Progenics | Current Liabilities            
Fair Value, Option, Quantitative Disclosures [Line Items]            
Contingent consideration liabilities   99,700   99,700    
Progenics | Cash Payments 2022            
Fair Value, Option, Quantitative Disclosures [Line Items]            
Contingent consideration liabilities $ 100,000          
Progenics | Cash Payments 2023            
Fair Value, Option, Quantitative Disclosures [Line Items]            
Contingent consideration liabilities $ 150,000          
Progenics | Net Sales Targets For Azedra            
Fair Value, Option, Quantitative Disclosures [Line Items]            
Potential payments, high   70,000   70,000    
Progenics | 1095 commercialization milestone            
Fair Value, Option, Quantitative Disclosures [Line Items]            
Potential payments, high   5,000   5,000    
Progenics | 1404 Commercialization Milestone            
Fair Value, Option, Quantitative Disclosures [Line Items]            
Potential payments, high   $ 10,000   10,000    
Royalty | Progenics            
Fair Value, Option, Quantitative Disclosures [Line Items]            
Company acquired right to receive certain future milestone       $ 5,000